IP Library Granted Patent US 11,000,527
Granted Patent B2
US 11,000,527 · App. 16/581,058 · Granted May 11, 2021

Therapeutic methods and compositions

Inventor: Bassam Damaj (San Diego, CA)
Assignee: INNOVUS PHARMACEUTICALS, INC.
A61K31/519A61K9/0014A61K9/0053A61K31/4525A61K36/67A61K45/06A61K47/02A61K47/12A61K47/38A61P15/10A61K31/198A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,000,527
App. No.
16/581,058
Granted
May 11, 2021
Kind
B2
Abstract

The invention provides compositions and methods that are effective to improve NO production in vivo and/or to increase NO levels in blood. Such compositions and methods may be useful to improve the effects of PDE 5 inhibitors, for example, on erectile dysfunction or pulmonary hypertension.

Claims (19)

1. A method to increase NO levels in the blood of a mammal, treat erectile dysfunction in a mammal, improve sexual function in a mammal, or improve cognitive function in a mammal, comprising administering a PDE 5 inhibitor and piperine to the mammal.

2. A method to improve erection hardness, erection maintenance, frequency of intercourse, partner satisfaction, or overall satisfaction with sexual health in a male human or to improve lubrication, sexual desire, ability to be aroused or frequency of intercourse, in a female human, comprising administering a PDE 5 inhibitor and piperine to the human.

3. The method of claim 1 wherein the PDE 5 inhibitor is sildenafil, tadalafil, or vardenafil.

4. The method of claim 1 wherein the PDE 5 inhibitor is sildenafil.

5. The method of claim 1 wherein the piperine is synthetically produced piperine.

6. The method of claim 1 wherein the piperine is an extract from the fruit of Piper.

7. The method of claim 1 wherein the PDE 5 and the piperine are administered at the same time.

8. The method of claim 1 wherein the PDE 5 and the piperine are administered at different times.

9. The method of claim 1 wherein piperine is administered to the mammal before the PDE 5 inhibitor is administered to the mammal.

10. The method of claim 1 wherein piperine is administered to the mammal in multiple doses over multiple days before the PDE 5 inhibitor is administered to the mammal.

11. The method of claim 1 wherein a composition that comprises piperine and a PDE 5 inhibitor is administered to the mammal.

12. The method of claim 1 further comprising administering L-citrulline or L-arginine to the mammal.

13. The method of claim 1 , further comprising administering L-citrulline and L-arginine to the mammal.

14. A composition comprising piperine and a PDE 5 inhibitor.

15. The composition of claim 14 wherein the PDE 5 inhibitor is sildenafil, tadalafil, or vardenafil.

16. The composition of claim 14 wherein the PDE 5 inhibitor is sildenafil.

17. The composition of claim 14 that is formulated for oral administration.

18. The composition of claim 14 that is formulated for topical administration.

19. The composition of claim 14 , further comprising L-citrulline, L-arginine, microcrystalline cellulose, silicon dioxide, and magnesium stearate.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: INNOVUS PHARMACEUTICALS, INC.
Reel/Frame 067728/0206 →
SECURITY INTEREST Recorded Feb 10, 2022
From: INNOVUS PHARMACEUTICALS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 058976/0706 →
SECURITY INTEREST Recorded Jan 27, 2022
From: INNOVUS PHARMACEUTICALS, INC.; SEMPRAE LABORATORIES, INC.
To: ECLIPSE BUSINESS CAPITAL LLC (F/K/A ENCINA BUSINESS CREDIT, LLC), AS AGENT
Reel/Frame 058789/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2021
From: DAMAJ, BASSAM
To: INNOVUS PHARMACEUTICALS, INC.
Reel/Frame 055512/0666 →
Continuity (3)
Continuation 15979120 · May 14, 2018
Provisional Application 62505514 · May 12, 2017
Related Publication 20200230143A1 · Jul 23, 2020